Business Wire

B2BROKER

Share
B2Broker Launches B2Margin White Label Margin Exchange Trading Platform

B2Broker , a leading liquidity and technology provider of solutions to the Forex and crypto industry, has announced the launch of B2Margin , a white label margin exchange trading platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005593/en/

Margin trading, long present in the Forex markets, is now hugely popular in the fast-moving crypto sphere. Even large exchanges have now implemented leveraged trading thanks to its high profit-potential which is not achievable with spot trading these days.

B2Broker CEO and Founder, Arthur Azizov comments, “Margin trading has really increased in popularity despite the fact that derivative trading is what everyone tried to avoid when this was all starting out. Back in 2016, all traders preferred spot trading but business is now moving further towards derivative trading, justifying our decision to develop B2Margin and offer an attractive margin trading solution to our clients”.

Crypto margin trading offers brokers several compelling advantages in terms of more trading opportunities. The threat of exchange hacks is also minimised since trading with leverage reduces the amount of capital that is required to be held by an exchange.

About B2Margin

B2Margin is a White Label Margin Exchange trading platform developed by B2Broker that includes a range of functions including on-boarding, compliance, risk management, pricing and trading analytics.

Offering traders the opportunity to boost their trading with leverage, B2Margin is designed with both institutional and retail clients in mind, supporting multiple asset classes, such as FX, Metals, Indices, Energies, Stocks, ETFs, Cryptocurrencies CFDs and Spot/Cash Cryptocurrencies, with Futures Cryptocurrencies in the pipeline. This means that every broker will be able to provide two solutions to their clients - either leverage or cash trading on all the asset classes outlined.

Furthermore, B2Broker is in the final stages of completing its dividend distribution module which will allow broker-dealers to provide liquidity for STOs shares and cash equities.

Professional and Adaptive GUI

B2Margin offers a vast range of features with an advanced interface which meets all requirements from beginners to professional traders. By providing a customizable and adaptive layout, end users get to choose what they wish to see according to their needs and preferences. Trading instruments are grouped by classes with a customisable workspace which includes intuitive visualisation of market data, an extensive suite of trading tools and complete branding customisation. Some of the main features include:

Multiple Order Types

B2Margin offers multiple order types to support the most sophisticated trading strategies and provide users with a variety of options on how and when to enter and exit a trade. From Protection orders to Time in Force up to Pending orders, traders have everything they need to manage their trading activity.

Professional Сharts

This enables users to place trades, manage orders and work directly from our integrated charts and utilise a comprehensive suite of drawing tools, as well as over 50 technical indicators to analyze price trends.

Secure Wallets

The ability to withdraw, deposit and store your assets in your personal secure wallet. All assets are securely held in our offline storage system to protect users against any possible risks and threats.

Watchlist

Users have the opportunity to add their favourite instruments to the list and keep an eye on their current prices and 24 hour changes. Orders can then be placed straight from the Watchlist.

Order Book

The list of buy and sell orders organized by price is updated in real time and is an important indicator of market depth, reflecting the trading instrument's likely price trend.

Customised Leverage

For precise risk management, a broker’s clients can set their own custom leverage for each trade order. This is a highly anticipated unique feature that provides a competitive advantage in attracting clients to a business.

Risk Management

Along with the standard way of managing risk known as A-Book or B-Book, B2Margin allows brokers to use C-Book - a highly advanced feature for each broker’s dealing department.

A broker dealer will also be able to customise their spread, markup, swap and commissions for each user, particular accounts and by group.

Tech Support

B2Broker offers all its clients 24/7 technical support.

These features, with the added benefit of detailed account statements to volume trade reports, allow brokers to get complete control over their operations and maximise their business potential.

A Complete Customised Solution in 4 Weeks

A complete B2Margin brokerage solution can be implemented in under 4 weeks once the associated legalities and financial aspects are settled. B2Margin also includes B2Broker’s client traders room solution, B2Core , which allows for client onboarding, processing deposits and withdrawals, KYC and a host of other functions for a successful Brokerage business operation. Finally, B2Margin supports FIX API connection enabling brokers to offer their clients the ultimate in trading performance.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye